Navigation Links
UV Flu Technologies to Commence a National TV Advertising Campaign

CENTERVILLE, Mass., May 16, 2012 /PRNewswire/ -- UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce that it has signed a television joint venture agreement with Stardust  International TV, of San Bernardino Ca., for the filming of a 60 second commercial, along with a 10 minute, "mini-infomercial." The commercial will run locally, regionally, and nationally, on a variety of television networks, including Comcast and Direct TV. The commercials will be run several hundred times to a potential audience of over 40 million households, while the mini-infomercial will run 4 times weekly to a variety of television stations.

"We think this is an outstanding opportunity to create brand awareness and sales for UV Flu," said Jack Lennon, President of UV Flu Technology. "Our FDA cleared device utilizes patented  break thru technology that eliminates the issues of maintenance and efficacy present in almost all but the most costly filter systems. The Viratech UV-400 patented technology kills airborne bacteria, reduces odors, volatile organic compounds, and a host of other airborne contaminants. Indoor Air Pollution has been shown to have direct links to sleep disorders, respiratory issues including asthma and allergies, cancer, diabetes and even the risk of stroke."

"Finally having a national TV commercial, that can educate the American consumer about the health benefits of using our device and breathing contaminant-free air indoors, we think will dramatically improve the awareness of our brand, and the importance of the whole space as well," said Mr. Lennon. "The recently announced launch of the Serta Ultimate Sleep System, which combines our Viratech air purifier, with one of Serta's finest memory foam mattresses, coupled with their local advertising and our new 60 second national commercial, should have a significant impact on long-term sales."

Further details regarding the Company's business, acquisitions, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's  ("SEC") EDGAR database. For more information, visit:

About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.)  The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device.

In addition, the Company's RxAir subsidiary in Dallas, TX, makes one of the worlds' finest lines of hospital-grade HEPA filtration products. The RX-3000, the Company's main product, is currently in almost 450 hospitals internationally, is FDA cleared as a Class II Medical Device, and has been shown to capture 99.99% of all airborne contaminants. The Company's product lines are in Hospitals, government buildings, casinos and restaurants around the world.

For more information, visit: Or

Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.


UV Flu Technologies, Inc.
John J. Lennon,  President & CEO

Investor Information:
Toll-Free: 1-877-358-5455




SOURCE UV Flu Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. MultiCell Technologies Announces Positive Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer In Vitro Models
2. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
3. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
4. AquaLiv Technologies, Inc. and Its Subsidiary, AquaLiv, Inc., Release Funding Updates
5. Webb Telescope spinoff technologies already seen in some industries
6. Leading Scientists to Debate Views on Rejuvenation Biotechnologies
7. ODT Forum Presents Regenerative Technologies
8. Oxford Finance and Silicon Valley Bank Provide $15 Million Senior Credit Facility to NanoString Technologies
9. Life Technologies Showcases Leading Technologies for Cancer Research at the AACR Annual Meeting 2012
10. Cobalt Technologies Hits Key Commercial Milestone with Pretreatment Process Demonstration
11. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
Post Your Comments:
(Date:10/10/2015)... 10 octobre 2015 Le 8 octobre, l,honorable Doris ... Registre du Congrès sa déclaration de soutien à ... autour du plasma (IPAW), qui se tiendra du ... Plasma Protein Therapeutics Association (PPTA) et ... , Sensibiliser l,opinion publique mondiale autour du ...
(Date:10/10/2015)... , 10. Oktober, 2015 Am ... (Abgeordnete der Demokratischen Partei für Kalifornien) ihre Würdigung ... 17. Oktober) in die Aufzeichnungen des Kongresses eintragen ... Protein Therapeutics Association (PPTA) und ihren Mitgliedsunternehmen ... , Hebung des Bewusstseins über Plasmaspenden weltweit ...
(Date:10/9/2015)... -- On October 8, the Honorable Doris O. Matsui ... the third annual International Plasma Awareness Week (IPAW), to ... Plasma Protein Therapeutics Association (PPTA) and its ... Raise global awareness about plasma donation , Recognize ... lives , Increase understanding about lifesaving plasma protein ...
(Date:10/9/2015)... , Oct. 9, 2015 Governor ... clinical stage biopharmaceutical company focused on developing T-cell receptor ... high-paying jobs with a new expansion project. ... news for the commonwealth as 110 new, high-paying jobs ... Tom Wolf . "My budget proposal includes sustained funding ...
Breaking Biology Technology:
... , , , Genetic reporter ... regulatory promoter and enhancer sequences as well as transcription factors. , ... enhancer) is cloned , together with the reporter ... used to transfect cells. Quantification of the reporter indirectly provides , ...
... , , , , Using eukaryotic ... to a hypoosmolar buffer system and short pulses in the s-range. , ... of sample resistance (patent pending)., , , ... Two cell lines (mouse fibroblast cells, human T-lymphocytes) were transfected ...
... , , , , , , PLG can be used ... The basic protocol given here works with E. coli cultures grown for 1214 , ... , ml Terrific Broth. , , ... 10,000 x g for 5 minutes at room , temperature. ...
Cached Biology Technology:
(Date:10/9/2015)... 09 2015 ... the "Samsung Galaxy S6 Fingerprint Sensor ... their offering. --> ) ... "Samsung Galaxy S6 Fingerprint Sensor - Reverse ... --> Research and Markets ( ...
(Date:10/8/2015)... , Oct. 8, 2015 Synaptics Inc. (NASDAQ: ... interface solutions, announced today that it will report ... 2016 on Thursday, October 22, 2015, after the ... corresponding conference call for analysts and investors at ... management may discuss forward-looking information.    ...
(Date:10/8/2015)... CITY , 8. Oktober 2015 /PRNewswire/ ... ein global tätiges Unternehmen des Bereiches Tracking, ... Vertrag mit der Gefängnisbehörde Virginias (Department of ... Rahmen elektronische Überwachungsdienste für alle Strafen geliefert ... Derek Cassell , Präsident für den Amerikanischen ...
Breaking Biology News(10 mins):
... South American rainforest and you may well see a ... fooled into thinking that they are all the same ... catfish, (reported in Nature 6.1.11), reveals that ... fish, could actually contain three or more different species. ...
... the kind of small-scale, often non-industrialized fisheries that millions ... community-based co-management. This is the conclusion of a study ... Nature . "The majority of the world,s fisheries ... with top-down rules and the means to enforce them," ...
... of environmental DNA (eDNA) by scientists from the University ... invasive Asian carp in the Chicago-area waterway has been ... peer-reviewed journal published by the Society for Conservation Biology. ... eDNA, a very important part of the process is ...
Cached Biology News:
... Epitope: aa 16-25 of human GSK3 ... Recommended Storage: Store vial at -20 C prior ... extended storage aliquot contents and freeze at -20 C or ... Family: Other Sub-Family: not ...
S-100 alpha/beta chain (8B10)...
... Acetate: CoA ligase (AMP forming), Acetate thiokinase ... protein content. Physical form: Lyophilized ... and reduced glutathione Preparation Unit ... of S-acetyl coenzyme A from acetate, ATP ...
SCCRO (S-17)...
Biology Products: